Skip to main content
SpringerLink
Log in

The benefit of angiotensin AT1 receptor blockers for early treatment of hypertensive patients

  • IM - REVIEW
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

ESC guidelines for management of arterial hypertension allow one to choose among five classes of antihypertensive drugs indiscriminately. They are based on the principle that in the management of hypertensive patients, it is fundamental to reduce blood pressure (BP), independently of the utilized drug. However, it has been demonstrated that the renin–angiotensin system (RAS) plays a relevant role in the hypertensive-derived development and progression of organ damage. Thus, antihypertensive drugs interfering with the RAS should be preferred in preventing and reducing target organ damage. The availability of two classes of drugs, ACE-inhibitors and angiotensin AT1 receptor blockers (ARBs), both interfering with the RAS, makes the choice between them difficult. Both pharmacological strategies offer an effective BP control, and a substantial improvement of prognosis in different associated pathologies. Regarding cardiovascular prevention, ACE-inhibitors have an extensive scientific literature regarding utility in high-risk patients. Nevertheless, there is evidence to support the concept that in the early phases of organ tissue damage, the RAS is activated, but the ACE pathway producing angiotensin II is not always employed. Accordingly, ACE-inhibitors appear to be less effective, whereas ARBs have a greater beneficial action in the initial stages of atherosclerotic disease. Moreover, patients undergoing ARBs therapy show a substantially lower risk of therapy discontinuation when compared to those treated with ACE-inhibitors, because of a better tolerability. In conclusion, ACE-inhibitors should be used in patients who have already developed organ damage, but tolerate this drug well, while ARBs should be the first choice in naïve hypertensive patients without organ damage or at the initial stages of disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34:2159–2219

    Article  PubMed  Google Scholar 

  2. Rendina D, Ippolito R, De Filippo G, Muscariello R, De Palma D, De Bonis S, Schiano di Cola M, Benvenuto D, Galderisi M, Strazzullo P, Galletti F, Strazzullo P, Galletti F (2017) Risk factors for silent ischemia in patients with well established essential hypertension. Intern Emerg Med 12:171–179

    Article  PubMed  Google Scholar 

  3. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, For the LIFE (Losartan Intervention for Endpoint Reduction) Study Group (2002) Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction (LIFE): a randomised trial against atenolol. Lancet 359:995–1003

    Article  CAS  PubMed  Google Scholar 

  4. Volpe M, Savoia C, De Paolis P, Ostrowska B, Tarasi D, Rubattu S (2002) The renin–angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. J Am Soc Nephrol 13:s173–S178

    Article  CAS  PubMed  Google Scholar 

  5. Borghi C, Task Force SIIA, Rossi F, SIF Task Force (2015) Role of the renin–angiotensin–aldosterone system and its pharmacological inhibitors in cardiovascular diseases: complex and critical issues. High Blood Press Cardiovasc Prev 22:429–444

    Article  CAS  PubMed  Google Scholar 

  6. Savarese G, Edner M, Dahlström U, Perrone-Filardi P, Hage C, Cosentino F, Lund LH (2015) Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction. Int J Cardiol 199:415–423

    Article  PubMed  Google Scholar 

  7. Evans M, Carrero JJ, Szummer K, Åkerblom A, Edfors R, Spaak J, Jacobson SH, Andell P, Lindhagen L, Jernberg T (2016) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in myocardial infarction patients with renal dysfunction. J Am Coll Cardiol 67:1687–1697

    Article  CAS  PubMed  Google Scholar 

  8. Molnar MZ, Kalantar-Zadeh K, Lott EH, Lu JL, Malakauskas SM, Ma JZ, Quarles DL, Kovesdy CP (2014) Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. J Am Coll Cardiol 63:650–658

    Article  CAS  PubMed  Google Scholar 

  9. The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) Investigators (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559

    Article  Google Scholar 

  10. The Heart Outcomes Prevention Evaluation Study (HOPE) Investigators (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145–153

    Article  Google Scholar 

  11. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmäki K, Dahlöf B, de Faire U, Mörlin C, Karlberg BE, Wester PO, Björck JE (1999) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353:611–666

    Article  CAS  PubMed  Google Scholar 

  12. ALLHAT Collaborative Research Group (2002) Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 288:2981–2995

    Article  Google Scholar 

  13. Lindon MH, Wing MB, Reid CM, Ryan P, Beilin LJ, Brown MA, For the Second Australian National Blood Pressure Study Group (2003) A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 348:583–592

    Article  Google Scholar 

  14. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J, ASCOT Investigators (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 16(366):895–906

    Article  Google Scholar 

  15. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ, HYVET Study Group (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:1887–1898

    Article  CAS  PubMed  Google Scholar 

  16. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 363:2022–2031

    Article  CAS  PubMed  Google Scholar 

  17. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC, MOSES Study Group (2005) Morbidity and mortality after stroke. Eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 36:1218–1226

    Article  CAS  PubMed  Google Scholar 

  18. Viazzi F, Bonino B, Cappadona E, Pontremoli R (2016) Renin angiotensin-aldosterone system blockade in chronic kidney disease: current strategies and look ahead. Intern Emerg Med 11:627–635. Intern Emerg Med 11:627–635

    Article  PubMed  Google Scholar 

  19. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456–1462

    Article  CAS  PubMed  Google Scholar 

  20. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW (2006) Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354:131–140

    Article  CAS  PubMed  Google Scholar 

  21. Carson P, Giles T, Higginbotham M, Hollenberg N, Kannel W, Siragy HM (2001) Angiotensin receptor blockers: evidence for preserving target organs. Clin Cardiol 24:183–190

    Article  CAS  PubMed  Google Scholar 

  22. Miura M, Sakata Y, Miyata S, Shiba N, Takahashi J, Nochioka K, Takada T, Saga C, Shinozaki T, Sugi M, Nakagawa M, Sekiguchi N, Komaru T, Kato A, Fukuchi M, Nozaki E, Hiramoto T, Inoue K, Goto T, Ohe M, Tamaki K, Ibayashi S, Ishide N, Maruyama Y, Tsuji I, Shimokawa H, SUPPORT Trial Investigators (2016) Influence of left ventricular ejection fraction on the effects of supplemental use of angiotensin receptor blocker olmesartan in hypertensive patients with heart failure. Circ J 80:2155–2164

    Article  PubMed  Google Scholar 

  23. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM, Rump LC, Viberti G, ROADMAP Trial Investigators (2011) Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364:907–917

    Article  CAS  PubMed  Google Scholar 

  24. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, For the Diabetic Exposed to Telmisartan and Enalapril Study Group (2004) Angiotensin-receptor versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952–1961

    Article  CAS  PubMed  Google Scholar 

  25. Tocci G, Volpe M (2011) End-organ protection in patients with hypertension: focus on the role of angiotensin receptor blockers on renal function. Drugs 71:1003–1017

    Article  CAS  PubMed  Google Scholar 

  26. Pitt B, Segal R, Martinez FA (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet 349:747–752

    Article  CAS  PubMed  Google Scholar 

  27. Pitt B, Poole-Wilson PA, Segal R (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival study—ELITE II. Lancet 355:1582–1587

    Article  CAS  PubMed  Google Scholar 

  28. Dickstein K, Kjekshus J, OPTIMAAL Steering Committee for the OPTIMAAL Study Group (2002) Effects of losartan and captopril on mortality and morbidity in high risk patients after acute myocardial infarction: the OPTIMAL randomised trial. Lancet 360:752–760

    Article  CAS  PubMed  Google Scholar 

  29. Pfeffer M, Mc Murray J, Velasquez E, Rouleau J-L, Kober L, Maggioni AP, For the VALIANT Investigators (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N Engl J Med 349:1893–1906

    Article  CAS  PubMed  Google Scholar 

  30. The EURopean trial On reduction of cardiac events with perindopril instable coronary Artery disease Investigators (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362:782–788

    Article  Google Scholar 

  31. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC (1995) A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333:1670–1676

    Article  PubMed  Google Scholar 

  32. Kjøller-Hansen L, Steffensen R, Grande P (2000) The angiotensin-converting enzyme inhibition post revascularization study (APRES). J Am Coll Cardiol 35:881–888

    Article  PubMed  Google Scholar 

  33. Rutherford JD, Pfeffer MA, Moyé LA, Davis BR, Flaker GC, Kowey PR, Lamas GA, Miller HS, Packer M, Rouleau JL (1994) Effects of captopril on ischemic events after myocardial infarction. Results of the survival and ventricular enlargement trial. SAVE Investigators. Circulation 90:1731–1738

    Article  CAS  PubMed  Google Scholar 

  34. Swedberg K, Held P, Kjekshus J, Rasmussen K, Rydén L, Wedel H (1992) Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 327:678–684

    Article  CAS  PubMed  Google Scholar 

  35. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342:821–828

    Google Scholar 

  36. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh NL, Hsia J, Pfeffer MA, Rice MM, Rosenberg YD, Rouleau JL (2004) Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 351:2058–2068

    Article  CAS  PubMed  Google Scholar 

  37. Volpe M (2008) A new option for therapeutic management of patients with cardiovascular disease. High Blood Press Cardiovasc Prev 15:47–51

    Article  PubMed  Google Scholar 

  38. Cuocolo A, Storto G, Izzo R, De Luca N, Trimarco B (1999) Effects of valsartan on left ventricular diastolic function in patients with mild or moderate essential hypertension: comparison with enalapril. J Hypertens 17:1759–1766

    Article  CAS  PubMed  Google Scholar 

  39. Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, Lacourcière Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JM, Thomas JD, Zile MR, Aurigemma GP, Valsartan In Diastolic Dysfunction (VALIDD) Investigators (2007) Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 369:2079–2087

    Article  CAS  PubMed  Google Scholar 

  40. Raff U, Ott C, Ruilope LM, Menne J, Haller H, Schmieder RE (2014) Prevention of electrocardiographic left ventricular remodeling by the angiotensin receptor blocker olmesartan in patients with type 2 diabetes. J Hypertens 32:2267–2276

    Article  CAS  PubMed  Google Scholar 

  41. Dzau V (2005) The cardiovascular continuum and renin–angiotensin–aldosterone system blockade. J Hypertens suppl 23:S9–S17

    Article  Google Scholar 

  42. Ahmad S, Simmons T, Varagic J, Moniwa N, Chappell MC, Ferrario CM (2011) Chymase-dependent generation of angiotensin II from angiotensin-(1–12) in human atrial tissue. PLoS ONE 6:e28501

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Cohn JN, Tognoni G (2001) A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667–1675

    Article  CAS  PubMed  Google Scholar 

  44. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, CHARM Investigators Committees (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 362:777–781

    Article  CAS  PubMed  Google Scholar 

  45. Paul M, Poyan Mehr A, Kreutz R (2006) Physiology of local renin-angiotensin systems. Physiol Rev 86:747–803

    Article  CAS  PubMed  Google Scholar 

  46. Corrao G, Zambon A, Parodi A, Poluzzi E, Baldi I, Merlino L, Cesana G, Mancia G (2008) Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 26:819–824

    Article  CAS  PubMed  Google Scholar 

  47. Burke TA, Sturkenboom MC, Lu S-E, Wentworth CE, Lin Y, Rhoads GG (2006) Discontinuation of hypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens 24:1193–1200

    Article  PubMed  Google Scholar 

  48. Bourgault C, Senecal M, Brisson M, Marentette MA, Gregoire JP (2005) Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens 19:607–613

    Article  CAS  PubMed  Google Scholar 

  49. Benetos A, Thomas F, Bean KE, Guize L (2003) Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens 21:1635–1640

    Article  CAS  PubMed  Google Scholar 

  50. Redon J, Cea-Calvo L, Lozano JV, Marti-Canales JC, Llisterri JL, Aznar J, González-Esteban J, PREV-ICTUS Study (2007) Differences in blood pressure control and stroke mortality across Spain: the Prevencion de Riesgo de Ictus (PREV-ICTUS) study. Hypertension 49:799–805

    Article  CAS  PubMed  Google Scholar 

  51. Volpe M, Agabiti Rosei E (2013) 2012 consensus document of the Italian Society of Hypertension (SIIA): strategies to improve blood pressure control in Italy. High Blood Press Cardiovasc Prev 20:45–52

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Advanced Biomedical Sciences, Federico II University Hospital, Via S. Pansini 5, bld 1, 80131, Naples, Italy

    Bruno Trimarco, Ciro Santoro & Maurizio Galderisi

  2. Dipartimento Medico e Chirurgico di Cuore e Vasi, Casa di Cura San Michele, Maddaloni, Caserta, Italy

    Marco Pepe

Authors
  1. Bruno Trimarco
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ciro Santoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marco Pepe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maurizio Galderisi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bruno Trimarco.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interests.

Statement of human and animal rights

This chapter does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

For this type of study formal consent is not required.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Trimarco, B., Santoro, C., Pepe, M. et al. The benefit of angiotensin AT1 receptor blockers for early treatment of hypertensive patients. Intern Emerg Med 12, 1093–1099 (2017). https://doi.org/10.1007/s11739-017-1713-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-017-1713-x

Keywords

Search

Navigation